DCEBIO

DCEBIO is a small/medium conductance calcium-activated potassium (SKCa/IKCa) channel opener and primary neuron signal blocker. It hyperpolarizes the membrane potential of C2C12 myoblasts by activating IKCa channels, thereby promoting myogenic differentiation. The specific biological activity of DCEBIO is manifested in increased myotube formation, enhanced myosin heavy chain II protein levels and myogenin mRNA levels. DCEBIO can be applied in the field of muscle research, especially in muscle-related degenerative diseases such as sarcopenia[1][2][3].

Product Specifications

CAS Number

[60563-36-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/dcebio.html

Concentration

10mM

Purity

99.25

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1NC2=CC(Cl)=C(Cl)C=C2N1CC

Molecular Formula

C9H8Cl2N2O

Molecular Weight

231.08

Precautions

H302, H315, H319, H335

References & Citations

[1]Tanaka S, et al. DCEBIO facilitates myogenic differentiation via intermediate conductance Ca2+ activated K+ channel activation in C2C12 myoblasts. J Pharmacol Sci. 2017 Apr;133 (4) :276-279.|[2]West CL, et al. Identification of SSRI-evoked antidepressant sensory signals by decoding vagus nerve activity. Sci Rep. 2021 Oct 26;11 (1) :21130.|[3]Iseki Y, et al. Opening of Intermediate Conductance Ca2+-Activated K+ Channels in C2C12 Skeletal Muscle Cells Increases the Myotube Diameter via the Akt/Mammalian Target of Rapamycin Pathway. J Pharmacol Exp Ther. 2021 Mar;376 (3) :454-462.